Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone

Philip D. Harvey, Masaaki Ogasa, Josephine Cucchiaro, Antony Loebel, Richard S.E. Keefe

Research output: Contribution to journalArticle

73 Scopus citations

Abstract

Background: Improving cognitive functioning in people with schizophrenia is a major treatment goal. In addition, interview-based measures have been developed to supplement performance-based assessments. However, few data are available regarding whether interview-based measures are sensitive to treatment-related changes. Methods: Adult outpatients who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomized to 21 days of double-blind treatment with lurasidone 120 mg once daily (N = 150) or ziprasidone 80 mg BID (N = 151). A similar proportion of patients completed the study on lurasidone (67.5%) and ziprasidone (69.3%). Study participants were assessed with the majority of the tests from the MATRICS Consensus Cognitive Battery (MCCB) and an interview-based assessment of cognitive functioning, the Schizophrenia Cognition Rating Scale (SCoRS). SCoRS ratings were based on the interviewer's best judgment, after interviews with the patient and a caregiver when available. The study was conducted from April 2006 to January 2007. Results: There were no between-group treatment differences in performance on the MCCB or the SCoRS ratings. Lurasidone patients demonstrated significant within group-improvement from baseline on the MCCB composite score (p = 0.026) and on the SCoRS (p < 0.001), but ziprasidone patients did not improve on either the MCCB composite (p = 0.254) or the SCoRS (p = 0.185). At endpoint there was a statistical trend (p = 0.058) for lurasidone to demonstrate greater improvement from baseline in SCoRS ratings. Improvements in interview-based aspects of cognition were not related to MCCB test changes, and had minimal correlations with changes in symptoms. Conclusions: These data suggest that interview-based cognitive measures such as the SCoRS may be sensitive to changes after 3 weeks of treatment in patients with schizophrenia. Lurasidone is being assessed further in ongoing clinical trials with additional outcome measures.

Original languageEnglish (US)
Pages (from-to)188-194
Number of pages7
JournalSchizophrenia Research
Volume127
Issue number1-3
DOIs
StatePublished - Apr 1 2011

Keywords

  • Antipsychotic
  • Lurasidone
  • Neuropsychology
  • Schizophrenia
  • Ziprasidone

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Fingerprint Dive into the research topics of 'Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone'. Together they form a unique fingerprint.

  • Cite this